Biopharma’s reawakened interest in cardiovascular diseases spans new targets and modalities, with more convenient formulations to boost access and adherence.
References
-
Mayor, S. BMJ https://doi.org/10.1136/bmj.k4700 (2018).
-
Gilliland, T. C. et al. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2023.02.050 (2023).
-
O’Donoghue, M. L. et al. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2024.05.058 (2024).
-
Nicholls, S. J. et al. JAMA https://doi.org/10.1001/jama.2024.24017 (2024).
-
Katsiki, N., Vrablik, M., Banach, M. & Gouni-Berthold, I. Pharmaceuticals https://doi.org/10.3390/ph18050753 (2025).
-
Chertow, G. M. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03043-1 (2024).
-
Tengesdal, I. W. et al. Front. Immunol. https://doi.org/10.3389/fimmu.2021.661323 (2021).
-
Wang, H. et al. Intern. Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.106985 (2020).
-
Deng, W. Q., Ye, Z. H., Tang, Z., Zhang, X. L. & Lu, J. J. Acta Pharm. Sin. B. https://doi.org/10.1016/j.apsb.2024.11.018 (2025).
-
Poznyak, A. V. et al. Front. Cardiovasc. Med. https://doi.org/10.3389/fcvm.2022.959285 (2022).
-
NCD Risk Factor Collaboration. Lancet. https://doi.org/10.1016/S0140-6736(21)01330-1 (2021).
-
Flack, J. M., Buhnerkempe, M. G. & Moore, K. T. Curr. Hypertens. Rep. https://doi.org/10.1007/s11906-023-01282-0 (2024).
-
Krug, A. W. et al. Int. J. Obes. https://doi.org/10.1038/sj.ijo.0803642 (2007).
-
Fish, K. M. et al. Circ. Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.112.971325 (2012).
-
Hulot, J. S. & Kupatt, C. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2023.10.028 (2024).
Rights and permissions
About this article
Cite this article
Senior, M. Heart matters: new treatments, tools and access channels. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02933-0
-
Published:
-
Version of record:
-
DOI: https://doi.org/10.1038/s41587-025-02933-0
